Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREASURE-CKD: Tirzepatide and Renal Function in Overweight or Obesity with Chronic Kidney Disease
2021-005273-47Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD), Overweight, obesity and 2 more comparing Tirzepatide MTD with Placebo (2 arms). Primary endpoint: Mean change from baseline in kidney oxygenation. Started May 2022; status: active.
02
Drugs
03
Conditions
chronic kidney disease (CKD)Overweightobesitytype 2 diabetes mellitus (T2DM)Non-alcoholic fatty kidney disease (NAFKD)
Beyond the preview
Go deeper on 2021-005273-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005273-47.